

Clean copies of the amended specification pages are attached as Appendix B.

IN THE CLAIMS\*

Under the title heading "CLAIMS" and before claim 1 add the following words:

--What is claimed is:--.

Kindly cancel claim 1.

Kindly amend the claims as follows:

2. (Amended) The method according to claim 7, wherein the agonist is a corticosteroid or a pharmacodynamic equivalent thereof.

3. (Amended) The method according to claim 2, wherein the corticosteroid is selected from the group consisting of cortisol, cortisone, cortisone acetate, corticosterone, prednisolone, prednisone, prednylidene, methylprednisolone, triamcinolone, betamethasone, dexamethasone, paramethasone, fluorcortolone, deflazacort, cloprednol and fludrocortisone, a pharmacodynamic equivalent thereof or a combination thereof.

4. (Amended) The method according to any one of claims 2, 3 or 7, wherein the addictive disease is selected from the group consisting of opiate dependency, psychostimulant dependency, hallucinogen and entactogen dependency, amphetamine dependency, LSD dependency, and MDMA

\* Applicants describe the specific amendments to the claims using the bracket and underline format in Appendix A, which is attached hereto.

09851817.050901

A1

Sub  
B1

(Ecstasy) dependency, nicotine addiction, cannabinoid dependency, cocaine addiction, "Crack" addiction, alcoholism or polytoxicomaniac addiction.

5. (Amended) A pharmaceutical composition for the treatment of an addictive disease comprising:

- a. an addictive drug responsible for the addictive disease or a pharmacodynamic equivalent thereof; or a second addictive drug or the pharmacodynamic equivalent thereof; and
- b. at least one agonist selected from the group consisting of a corticosteroid receptor, a mineralo-corticosteroid receptor or a combination thereof.

6. (Amended) The pharmaceutical composition according to claim 5 wherein the addictive drug or a pharmacodynamic equivalent thereof is in a high dose and wherein the maintenance dose of at least one corticosteroid agonist is in the amount of 0.5-100 mg/day and 2 to 10 times higher amount for the initial dosage for a patient having a body weight of 60-80 kg.

7. (Amended) A method of treating an addictive disease caused by an addictive drug or in connection with the addictive drug comprising the step of administering a composition comprising:

- a. at least one agonist selected from the group consisting of a corticosteroid receptor, a mineralo-corticosteroid receptor, or a combination thereof; and
- b. the addictive drug or a pharmacodynamic equivalent thereof.